Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $5.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 293.70% from the stock’s current price.
Separately, StockNews.com assumed coverage on shares of Sangamo Therapeutics in a research report on Sunday, July 28th. They set a “sell” rating for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $2.67.
Get Our Latest Stock Report on Sangamo Therapeutics
Sangamo Therapeutics Stock Performance
Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $11.40 million. Sell-side analysts forecast that Sangamo Therapeutics will post -0.47 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Sangamo Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System lifted its stake in Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 23,650 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Sangamo Therapeutics during the second quarter worth $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Sangamo Therapeutics during the second quarter worth $89,000. Marshall Wace LLP lifted its stake in shares of Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 207,476 shares during the last quarter. Finally, Vontobel Holding Ltd. boosted its holdings in shares of Sangamo Therapeutics by 412.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock valued at $259,000 after acquiring an additional 241,440 shares in the last quarter. 56.93% of the stock is currently owned by institutional investors and hedge funds.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
Further Reading
- Five stocks we like better than Sangamo Therapeutics
- What Are the U.K. Market Holidays? How to Invest and Trade
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- What Are Dividends? Buy the Best Dividend Stocks
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.